GlycoEra
Bioprocessing · Drug Discovery
1open role
1backers · Sofinnova Partners
10+team · employees, estimated range
2020founded
Overview
GlycoEra is a biotechnology company developing a novel protein expression technology for biologic drug candidates. Its scientists work on upstream process development, fermentation and cell-culture processes and on analytics. The company is based in Wädenswil, Switzerland, with a further office listed in Newton, Massachusetts.
Funding and backers
Team
11-50
employees, estimated range
Hiring now
1
open roles
Backers
1
Sofinnova Partners
Momentum
15/100
in the news
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Sep 16
New executive GlycoEra Appoints Andrea Matthews as Chief Business Officer to Support Next Phase of Company Growth · glycoera.com
Jan 8
New executive GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline · manilatimes.net
2020
Founded
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Differential Bio is a biotechnology company that works on making microbial growth predictable and scalable through robotic lab automation…
PeptiMatrix™ delivers a defined peptide hydrogel platform for reproducible 3D cell culture in drug discovery and preclinical research.
Difficult protein production made simple. A next-generation expression system for next-generation therapeutics.
PROTEINA is a South Korean biotechnology company that uses its own SPID single-molecule protein-protein interaction detection technology to…
Adaptyv Bio is a biotechnology and synthetic biology platform company headquartered in Lausanne, Switzerland. Founded in 2021 by Julian…
Patented ELAREM™ cell culture supplements: Human Platelet Lysate (HPL) xeno-free NEW: Artificial HPL PL BioScience.
Jobs
≈ $82k – $186k per year (Estimated) · In office · Full-Time · 5+ years exp · PhD · Wädenswil
Cell Culture
Bioreactors
Apply
Growth
Hiring Momentum
48/100
Stable
Open positions
1
0 opened / 1 closed in 30 days
Median time-to-fill
187 days
faster than 6% of the market
ATS activity
Every ~10 hours
Today
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▲
Activity Timeline
Added Cell Culture to stack
Oct 2026
Added Bioreactors to stack
Oct 2026
Tech stack
Technologies named in job postings at GlycoEra over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
43/100
Practices & domains
Bioreactors
Cell Culture
Sign in to see how your skills match this stack
Sign In
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Sofinnova PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
GlycoEra Appoints Andrea Matthews as Chief Business Officer to Support Next Phase of Company Growth
Newton, MA & Wädenswil, Switzerland - September 16, 2026- GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders for the treatment of autoimmune diseases, today announced the appointment of Andrea Matthews as Chief B
Read more
Report
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
Dr. Duda to apply deep expertise in rare and immune-mediated diseases Newton, MA & Wädenswil, Switzerland - January 8, 2026 - GlycoEra AG, a biotechnology company pioneering best-in-class extracellular protein degraders, today announced the appointment of
Read more
Report
GlycoEra Appoints Petra Duda, M.D., Ph.D., as Chief Medical Officer to Advance Precision Immune Degrader Pipeline
Read more
Report
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
Financing led by Novo Holdings with significant support from world-class group of existing and new investors Proceeds from financing to support development of first-in-class IgG4-targeted protein degrader program through clinical proof-of-concept and the
Read more
Report
GlycoEra AG Raises $130 Million to Advance Novel Pipeline of Extracellular Protein Degraders for the Treatment of Autoimmune Diseases
Read more
Report
Report
GlycoEra AG Announces New Investor, Appoints Industry Veteran Greg Fralish as Chief Business Officer
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Wädenswil
Wädenswil
Switzerland
HQ
1 open roles 1 posted in 90 days 100% engineering 10-50 est. staff
hires for Science & Research